Studies

300 studies (first 300) · Download as JSON

• EASL-EASD-EASO Guidance for the Use of Resmetirom and Semaglutide as MASH-Targeted TherapyGuideline · 2026 · Not rated · Population unclear · Unclear
• Therapeutic modulation of the gut-brain axis in alcohol use disorder: A systematic reviewSystematic review · 2026 · Not rated · Partial match · Benefit
• Do glucagon-like peptide-1 receptor agonists influence cervical fusion outcomes? A systematic review and meta-analysisMeta-analysis · 2026 · Study tier 3 · Population unclear · Null
• Fat and lean mass changes during incretin-based therapy with structured exercise and nutritional support: A retrospective real-world pilot studyCase series · 2026 · Study tier 4 · Population unclear · Unclear
• Incretin-based injectable strategies versus intensified insulin for treatment intensification and simplification in type 2 diabetes: a systematic review and meta-analysisMeta-analysis · 2026 · Study tier 2 · Different population · Benefit
• Evaluation of clinical relevance of weight nadirs and weight regain during 3 years of treatment with tirzepatide in participants with obesity or overweight and prediabetesRandomized trial · 2026 · Study tier 3 · Different population · Unclear
• GLP-1 receptor agonists in elective spine surgery: a systematic review of fusion outcomes, perioperative safety, and procedure-specific riskSystematic review · 2026 · Not rated · Population unclear · Mixed
• Evaluating the safety of glucagon-like peptide-1 agonist use in non-diabetic overweight patients undergoing shoulder arthroplastyRetrospective cohort · 2026 · Study tier 3 · Different population · Mixed
• Integrating incretin-based therapies into comprehensive obesity care: an EASO position statementGuideline · 2026 · Not rated · Different population · Unclear
• Tirzepatide Initiation in Lithium-Treated Bipolar Disorder: Renal Biomarker Trajectories and Lithium Safety Signals Over 12 Months in a Real-World CohortRetrospective cohort · 2026 · Study tier 4 · Partial match · Unclear
• Current review of glucagon-like peptide 1 receptor agonists and risk of nonarteritic anterior ischemic optic neuropathyNarrative review · 2026 · Not rated · Population unclear · Harm direction
• Four Pillars in Type 2 Diabetes and Chronic Kidney Disease G4-G5: Mission Impossible-or Not Too Late to Start?Narrative review · 2026 · Not rated · Different population · Unclear
• Real-World Metabolic Improvements in Women With and Without Polyendocrine Metabolic Syndrome via a Multidisciplinary Telehealth Care PlatformRetrospective cohort · 2026 · Study tier 3 · Different population · Benefit
• GLP-1 receptor agonist therapy and incident atrial fibrillation in non-diabetic adults with obesity and chronic kidney disease: a propensity matched cohort studyRetrospective cohort · 2026 · Study tier 3 · Different population · Benefit
• GLP-1 receptor agonist treatment and cardiovascular outcomes following aortic valve replacement: a nationwide observational studyRetrospective cohort · 2026 · Study tier 3 · Partial match · Benefit
• Glucagon-Like Peptide-1 Receptor Agonists and Incident Cardiovascular Events and Death in Treated Serious Mental Illness, Type 2 Diabetes, and ObesityRetrospective cohort · 2026 · Study tier 3 · Different population · Benefit
• GLP-1 receptor agonist use and contrast-associated acute kidney injury after contrast-enhanced CT and CT angiography in adults with type 2 diabetes and chronic kidney disease: a propensity score-matched cohort studyRetrospective cohort · 2026 · Study tier 3 · Different population · Benefit
• Retatrutide treatment in streptozotocin-induced diabetic rats: renal inflammatory cytokines, HIF‑1α expression, and histopathological injury profileAnimal study · 2026 · Study tier 4 · Not human evidence · Mixed
• GLP-1 Receptor Agonist Use Before Total Knee Arthroplasty is Associated With Lower Postoperative MI, DVT, and VTE RatesRetrospective cohort · 2026 · Study tier 3 · Population unclear · Mixed
• Clinical Feasibility of a Low-Dose Tirzepatide Strategy in Older Adults with Type 2 Diabetes: Persistence, Metabolic Benefit, and Treatment Simplification in a Real-World CohortRetrospective cohort · 2026 · Study tier 4 · Different population · Unclear
• Impact of GLP-1 Agonists on Post-Operative Outcomes in Aesthetic & Body Contouring Surgery: A Systematic Review & Meta-AnalysisMeta-analysis · 2026 · Study tier 3 · Population unclear · Harm direction
• Effects of Sitagliptin Combined with GTS-21 on Improving Glycemic Control and Diabetic Nephropathy by Anti-Apoptosis in Leprdb/db MiceAnimal study · 2026 · Study tier 4 · Not human evidence · Mixed
• GLP-1 receptor agonists and hair loss: adverse effect, epiphenomenon, or therapeutic paradox?Narrative review · 2026 · Not rated · Population unclear · Mixed
• GLP-1 Receptor Agonists in Dentistry: Promise, Pitfalls, and Evidence GapsNarrative review · 2026 · Not rated · Population unclear · Mixed
• Liraglutide ameliorates obese type 2 diabetes by regulating macrophage cholesterol metabolism and H3K27ac modification to promote M2 polarization and adipocyte thermogenic activationAnimal study · 2026 · Study tier 4 · Not human evidence · Benefit
• Effects of glucagon-like peptide-1 (GLP-1) mono-agonists on reward processing in animal models: a systematic reviewSystematic review · 2026 · Not rated · Not human evidence · Unclear
• GLP-1 Receptor Agonist Therapy Is Associated With Lower Risk of Lower Extremity Amputation in Adults With Type 2 Diabetes and Foot Ulcer Without Coded Peripheral Arterial Disease: A Hypothesis-Generating Real-World Cohort StudyRetrospective cohort · 2026 · Study tier 3 · Different population · Benefit
• Efficacy and safety of HRS-7535, a novel oral small-molecule glucagon-like peptide-1 receptor agonist, in participants with type 2 diabetes mellitus inadequately controlled by metformin and sodium-glucose co-transporter 2 inhibitors: a multicentre, randomised, double-blind, placebo-controlled, parallel-group Phase II trialRandomized trial · 2026 · Study tier 3 · Different population · Benefit · Industry funded
• Risk of recurrent acute pancreatitis with GLP-1 receptor agonists after prior pancreatitis: a systematic reviewSystematic review · 2026 · Study tier 3 · Different population · Null
• Effects of tirzepatide (GIP/GLP-1 dual receptor agonist) on cardiorenal biomarkers and functional capacity in heart failure: a systematic review and meta-analysisMeta-analysis · 2026 · Study tier 2 · Different population · Benefit
• Endothelial AGGF1 contributes to glomerular barrier dysfunction via TNFSF12/FN14-Src-VE-cadherin signaling in diabetic kidney diseaseAnimal study · 2026 · Study tier 4 · Not human evidence · Benefit
• The Effects of GLP-1RA-Based and SGLT2 Inhibitor Therapy on Perirenal Adipose Tissue in CKD PatientsProspective cohort · 2026 · Study tier 3 · Population unclear · Benefit
• Audiovestibular adverse event reporting profiles of GLP-1 receptor agonists: A case-case pharmacovigilance study using FDA AEMS dataPharmacovigilance · 2026 · Study tier 4 · Population unclear · Unclear
• Real-World Twelve-Month Weight Loss Outcomes in a Comprehensive Obesity Care Program Utilizing Individualized Nutrition Therapy and Incretin-Based Obesity MedicationsRetrospective cohort · 2026 · Preliminary · Population unclear · Unclear · Not peer reviewed
• Characterizing the adverse event profile of semaglutide: A comprehensive U.S. food and drug administration adverse event reporting system-based pharmacovigilance studyPharmacovigilance · 2026 · Study tier 4 · Population unclear · Harm direction
• Tirzepatide use in adolescents with metabolic dysfunction-associated steatotic liver disease (MASLD): A case seriesCase series · 2026 · Study tier 4 · Different population · Unclear
• A GLP-1/apelin dual receptor agonist shows neuroprotective effects in the MPTP mouse model of Parkinson's diseaseAnimal study · 2026 · Study tier 4 · Not human evidence · Mixed
• Preconception incretin therapy reduces pregnancy and cardiometabolic outcomes in polycystic ovary syndromeRetrospective cohort · 2026 · Study tier 3 · Different population · Benefit
• Exploring semaglutide for alcohol use disorder: A review of clinical efficacy and neurobiological mechanismsNarrative review · 2026 · Not rated · Partial match · Benefit
• Short-term clinical efficacy and recorded adverse events of semaglutide combined with dapagliflozin in patients with type 2 diabetes mellitus and chronic kidney diseaseRetrospective cohort · 2026 · Study tier 4 · Different population · Benefit
• Cardiovascular Risk in SELECT-Eligible MI Patients With Overweight or Obesity: The Western Denmark Heart RegistryRetrospective cohort · 2026 · Not rated · Different population · Unclear
• Status Of GLP-1 drugs and their application in treating substance use disorders: A systematic reviewSystematic review · 2026 · Not rated · Population unclear · Mixed
• <span data-teams="true">A GPCR-Signaling Addiction Hub in the Murine Nucleus Accumbens and Its Partial Restitution by a GLP-1 Receptor Agonist: A Retrospective Transcriptomic AnalysisAnimal study · 2026 · Preliminary · Not human evidence · Unclear · Not peer reviewed
• Tirzepatide alleviates hepatic steatosis and inflammation in MASLD partly through suppression of macrophage Dectin-1/Syk/NF-κB signalingAnimal study · 2026 · Study tier 4 · Not human evidence · Benefit
• Combined empagliflozin and liraglutide therapy protects against tacrolimus-induced pancreatic and renal injury associated with oxidative stress reductionAnimal study · 2026 · Study tier 4 · Not human evidence · Benefit
• Real-World Anthropometric Outcomes, Safety, and Use Patterns of GLP-1 and Dual GIP/GLP-1 Receptor Agonists in Obesity and Glucose Metabolism Disorder: A Nationwide Multicentre Community Pharmacy StudyDesign unknown · 2026 · Study tier 4 · Different population · Unclear
• Kidney Outcomes With GLP-1 Receptor Agonists and Tirzepatide Versus Finerenone in Type 2 Diabetes and Chronic Kidney Disease: A Real-World Cohort StudyRetrospective cohort · 2026 · Study tier 3 · Different population · Mixed
• Adverse Oral and Salivary Effects Associated With Glucagon-Like Peptide-1 Receptor Agonists: Clinical InsightsNarrative review · 2026 · Not rated · Different population · Unclear
• GLP-1R expression and dermatological diseases: a mendelian randomization and real-world studyMendelian randomization · 2026 · Study tier 3 · Population unclear · Mixed
• Association of GLP1-Receptor Agonist Use With Frailty and Falls in Adults With Type 2 DiabetesRetrospective cohort · 2026 · Study tier 3 · Different population · Benefit
• Efficacy and Safety of Chemically Synthesized Semaglutide Injection (HD1916) for the Treatment of Obesity: A Multicenter, Randomized, Phase III TrialRandomized trial · 2026 · Study tier 2 · Different population · Null
• An RNA thermogenic therapy to preserve lean mass and enhance metabolic health during GLP-1 weight lossAnimal study · 2026 · Study tier 4 · Not human evidence · Benefit
• Design and baseline characteristics of the CagriSema cardiovascular outcomes trial (REDEFINE 3)Randomized trial · 2026 · Not rated · Different population · Unclear · Industry funded
• GLP-1 receptor agonists for obstructive sleep apnea: a meta-analysis of randomized controlled trialsMeta-analysis · 2026 · Study tier 2 · Different population · Mixed
• GLP-1 Receptor Agonists and Dual GIP/GLP-1 and Reduction in Major Cardiovascular Events: A Systematic Review and Network Meta-AnalysisSystematic review · 2026 · Not rated · Different population · Unclear · Not peer reviewed
• Post-Initiation Care Patterns and Weight Loss With Semaglutide and Tirzepatide for Obesity in Clinical PracticeRetrospective cohort · 2026 · Preliminary · Different population · Unclear · Not peer reviewed
• Semaglutide, independent of weight loss, attenuates cardiac and hepatic remodelling in experimental heart failure with preserved ejection fractionAnimal study · 2026 · Study tier 4 · Not human evidence · Benefit
• GLP-1 Receptor Agonists and Risk of Kidney Replacement Therapy and Health Care Utilization in Bipolar Disorder With Chronic Kidney DiseaseRetrospective cohort · 2026 · Study tier 3 · Different population · Mixed
• Oral small-molecule GLP-1RA safiglipron versus dapagliflozin in type 2 diabetes: a randomized, double-blind, active-comparator-controlled phase 3 trialRandomized trial · 2026 · Study tier 2 · Different population · Mixed
• Effects of GLP-1 receptor agonists on aesthetic surgery practice: A contemporary reviewNarrative review · 2026 · Not rated · Different population · Unclear
• Glucagon-like peptide-1 receptor agonists in hidradenitis suppurativa: A nationwide cohort studyRetrospective cohort · 2026 · Not yet reviewed
• Nisotirostide (LY3457263), a novel NPY2 receptor agonist for type 2 diabetes and obesity: From discovery to clinical proof of conceptAnimal study · 2026 · Not yet reviewed
• Tirzepatide attenuates cardiac microvascular injury and ferroptosis-related lipid peroxidation in diabetic mice: endothelial responses in the context of partial PRKN silencingAnimal study · 2026 · Not yet reviewed
• Effects of semaglutide on kidney disease in type 2 diabetes: a randomized placebo-controlled trialRandomized trial · 2026 · Not yet reviewed
• Nephroprotective Effects of the Dual GCGR/GLP-1R Agonist Survodutide in Hypertension-Accelerated Diabetic Kidney DiseaseAnimal study · 2026 · Not yet reviewed
• Pharmacological treatment strategies to prevent heart failure across the cardiovascular-kidney-metabolic spectrum: an EJHF Expert Consensus StatementGuideline · 2026 · Not yet reviewed
• Tirzepatide safety in EudraVigilance: descriptive and disproportionality analysis of preferred terms related to suboptimal treatment outcomes and drug-use-related issuesPharmacovigilance · 2026 · Not yet reviewed
• Survodutide Once Weekly in Adults with Obesity and Type 2 DiabetesRandomized trial · 2026 · Not yet reviewed
• Effects of Blueberry and Collard Greens Dietary Intervention on Metabolic and Inflammatory Biomarkers in Zucker Obese RatsRandomized trial · 2026 · Not yet reviewed
• GLP-1 Receptor Agonists and Insulin Versus Insulin for Perioperative Glycemic Control in Patients with Type 2 Diabetes Undergoing Cardiac Surgery: A Systematic ReviewSystematic review · 2026 · Not yet reviewed
• Effects of GLP-1 Receptor Agonists and Dual GIP/GLP-1 Receptor Agonists on Inflammatory and Metabolic Biomarkers in Type 2 Diabetes: A Systematic Review and Meta-AnalysisMeta-analysis · 2026 · Study tier 3 · Different population · Benefit
• Effects of semaglutide and empagliflozin on markers of endothelial function in persons with type 2 diabetes: A post hoc analysis of a randomized clinical trialRandomized trial · 2026 · Not yet reviewed
• A Systematic Review and Meta-Analysis of Malnutrition and Metabolic Failure in High-Potency Incretin TherapyMeta-analysis · 2026 · Not yet reviewed
• Patient-Reported Continuity of GLP-1 Receptor Agonist TherapyRetrospective cohort · 2026 · Not yet reviewed
• Comparative Efficacy of Tirzepatide Versus Semaglutide for Weight Loss in Adults With Overweight or Obesity: A Systematic Review and Meta-Analysis of Head-to-Head StudiesMeta-analysis · 2026 · Not yet reviewed
• Oral semaglutide for weight loss and liver fibrosis in overweight and obesity: A randomized controlled trialRandomized trial · 2026 · Not yet reviewed
• Weight Reduction Heterogenicity and Mediators of GLP-1RAs and Dual Agonists for Individuals With Obesity: A Meta-AnalysisMeta-analysis · 2026 · Not yet reviewed
• Real-world Evidence for Improvements in Inflammation and Anemia Biomarkers After the Initiation of GLP-1RA in Patients Receiving HemodialysisRetrospective cohort · 2026 · Not yet reviewed
• Glucagon-Like Peptide-1 Agonists and the Incidence of Atrial Fibrillation in Obese Patients With Heart Failure With Preserved Ejection Fraction and No DiabetesRetrospective cohort · 2026 · Not yet reviewed
• Genetic Insights Into Protective Effects of GLP-1 Receptor Agonists on Stroke and Alzheimer Disease Across AncestriesMendelian randomization · 2026 · Not yet reviewed
• GLP-1R agonist semaglutide protects human forebrain organoids from cholesterol-induced neurotoxicityCell / in-vitro · 2026 · Not yet reviewed
• Gastrointestinal adverse effects of GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists: A narrative expert review of approved therapies, oral formulations, and pipeline agentsPharmacovigilance · 2026 · Not yet reviewed
• The effect of SGLT2 inhibitors, GLP-1 receptor agonists, or DPP-4 inhibitors on stroke risk in type 2 diabetes: a nationwide longitudinal cohort study in Sweden with contextualisation analysisProspective cohort · 2026 · Not yet reviewed
• Gut-kidney signaling is impaired in individuals with type 2 diabetesCrossover trial · 2026 · Not yet reviewed
• Preventing Weight Regain After Glucagon-Like Peptide‑1 Therapy Discontinuation: A Pilot Randomized Controlled TrialRandomized trial · 2026 · Not yet reviewed
• A Novel Dual Therapy for Diabetic Ischemic Heart Injury: Sinomenine and Liraglutide Restore Mitochondrial Homeostasis and Suppress PyroptosisAnimal study · 2026 · Not yet reviewed
• The Effect of Glucagon-Like Peptide 1 Receptor Agonists on Peri- and Postmenopausal Breast Cancer OutcomesRetrospective cohort · 2026 · Not yet reviewed
• Cardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes at increased cardiovascular risk (ACHIEVE-4): a phase 3, event-driven, randomised, open-label, non-inferiority, active comparator trialRandomized trial · 2026 · Not yet reviewed
• Endothelial-Fibroblast Organoids Generated in Hydrogel Microchamber Arrays: A Translational Model of Vascular Dysfunction in Cardio-Kidney-Metabolic DiseaseCell / in-vitro · 2026 · Not yet reviewed
• Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trialRandomized trial · 2026 · Study tier 2 · Different population · Benefit · Industry funded
• Efficacy and Safety of Dual GLP-1/Glucagon Receptor Agonism in Overweight and Obesity: A Class-Specific Systematic Review and Meta-AnalysisMeta-analysis · 2026 · Study tier 2 · Different population · Benefit
• GHRH and GLP-1 receptor agonism promote human β-cell survival and improve glucose homeostasis in diabetic miceAnimal study · 2026 · Not yet reviewed
• Comparative Weight-Loss Outcomes Following Initiation of GLP-1 Receptor Agonists versus SGLT2 Inhibitors: A Real-World Active Comparator StudyRetrospective cohort · 2026 · Not yet reviewed
• Comparative outcomes of GLP-1 receptor agonist and SGLT2 inhibitor users after liver transplantation: An emulated target trialRetrospective cohort · 2026 · Not yet reviewed
• Positive modulation of glucagon-like peptide 1 (GLP-1) receptor by endogenous haemorphins with implications in glucose metabolism and diabetesAnimal study · 2026 · Not yet reviewed
• Comparative Renal Effectiveness of GLP-1RA and SGLT2i in US Veterans with Type 2 Diabetes and CKDRetrospective cohort · 2026 · Not yet reviewed
• Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of ObesityRandomized trial · 2026 · Not yet reviewed
• Genetically Proxied GIP-GIPR Pathway Perturbation and Fracture RiskMendelian randomization · 2026 · Not yet reviewed
• Oral small-molecule GLP-1 receptor agonist safiglipron in early type 2 diabetes: a randomized, double-blind, placebo-controlled trialRandomized trial · 2026 · Not yet reviewed
• Increasing Direct-to-Consumer Use of Semax and Selank Peptides Decoded from LLM-Curated Clinical Notes and Physician AdjudicationRetrospective cohort · 2026 · Not peer reviewed · Not yet reviewed
• The dual incretin agonist tirzepatide blunts nicotine-induced behaviours and neurochemistry in male miceAnimal study · 2026 · Not yet reviewed
• Non-Arteritic Anterior Ischaemic Optic Neuropathy Associated with Semaglutide usePharmacovigilance · 2026 · Not yet reviewed
• No Heavy Drinking Days and Percentage of Days Abstinent in a Randomized Trial of Adjunctive Ketamine for Alcohol Use Disorder: Secondary Analysis of the KARE TrialRandomized trial · 2026 · Not peer reviewed · Not yet reviewed
• Effectiveness of Adding GLP-1 Receptor Agonists to SGLT2 Inhibitor Therapy in Chronic Kidney Disease: A Population Based StudyRetrospective cohort · 2026 · Not yet reviewed
• Hypothalamic obesity in pediatric vs. adult craniopharyngioma: mechanisms, management, and cardiometabolic outcomesCase series · 2026 · Not yet reviewed
• Discovery of Fisetin as a potent and cell-active ACVR2A inhibitorCell / in-vitro · 2026 · Not yet reviewed
• GLP-1 Receptor Agonists in Heart Failure: A Systematic Review and Meta-analysis with Phenotype-Specific Effects and Dual Analytical FrameworksMeta-analysis · 2026 · Not yet reviewed
• Suitability of the ICH S1B(R1) Weight-of-Evidence Framework to Evaluate Glucagon-Like Protein-1 Receptor Agonist (GLP-1RA) Carcinogenicity RiskAnimal study · 2026 · Not yet reviewed
• Outcomes of GLP-1 Receptor Agonist Therapy after Liver Transplantation in Patients with Type 2 Diabetes: A Real-World Cohort StudyRetrospective cohort · 2026 · Not yet reviewed
• New-Onset Heart Failure in Patients with Obesity using Tirzepatide or SemaglutideRetrospective cohort · 2026 · Not peer reviewed · Not yet reviewed
• Real-world effectiveness of 6-month tirzepatide therapy on body weight and composition in adults with overweight and obesityRetrospective cohort · 2026 · Not yet reviewed
• Effects of Reimbursement Policy Change on Utilization of Injectable Semaglutide for Type 2 Diabetes and on Glycemic Control Among Discontinuers: A Danish Nationwide Cohort StudyRetrospective cohort · 2026 · Not peer reviewed · Not yet reviewed
• Clinical outcomes associated with glucagon-like peptide-1 receptor agonist therapy in patients with peripheral artery disease and diabetesRetrospective cohort · 2026 · Not yet reviewed
• GLP-1 Receptor Agonists in Dermatology: Prescribing Frameworks, Access, and the Emerging PipelinePharmacovigilance · 2026 · Not yet reviewed
• Trends in GLP-1 Receptor Agonist Prescribing Without an Apparent FDA-Approved IndicationRetrospective cohort · 2026 · Not yet reviewed
• Real-world cardiovascular effects of liraglutide: transportability analysis of the LEADER trialRetrospective cohort · 2026 · Not yet reviewed
• Future GLP-1 receptor co-agonists and their cardiac effectsAnimal study · 2026 · Not yet reviewed
• Semaglutide reduces proteomic organ-specific biological age across randomized clinical trialsRandomized trial · 2026 · Not peer reviewed · Not yet reviewed
• Targeting PFKFB3 Metabolic Gatekeeping of β-Cell Dysfunctional States Enables Durable Glucose Tolerance in Type 2 DiabetesAnimal study · 2026 · Not peer reviewed · Not yet reviewed
• Cardiovascular Outcomes in Patients with Type 2 Diabetes and Heart Failure with Reduced Ejection using Glucagon-like Peptide-1 Receptor AgonistsRetrospective cohort · 2026 · Not peer reviewed · Not yet reviewed
• GLP-1 Analogues and Long-term Outcomes in Adults with Obesity and Elevated CRP: A Real-world Matched Cohort StudyRetrospective cohort · 2026 · Not yet reviewed
• Comparative Risk of Nonarteritic Anterior Ischemic Optic Neuropathy Among Glucagon-Like Peptide-1 Receptor Agonists: An Integrated Safety and Mechanistic AnalysisPharmacovigilance · 2026 · Not yet reviewed
• Modulation of circulating osteocalcin-expressing monocytes by glucagon like peptide-1 receptor agonists in type 2 diabetes: an exploratory pilot studyCell / in-vitro · 2026 · Not yet reviewed
• Oral Semaglutide in Routine Clinical Practice: 24-Month Real-World Effectiveness, Persistence and Safety in Adults With Type 2 DiabetesRetrospective cohort · 2026 · Not yet reviewed
• Safety of Sodium/Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes and CKDRetrospective cohort · 2026 · Not yet reviewed
• Real-World Adverse Event Reporting Patterns of Tirzepatide Versus Semaglutide: A Stratified Study of General and Healthcare Professional Cohorts in FAERSPharmacovigilance · 2026 · Not yet reviewed
• Hair and Scalp Effects of GLP-1 Receptor Agonists in PracticePharmacovigilance · 2026 · Not yet reviewed
• GLP-1 Receptor Agonists, Stroke, and Cognitive Outcomes: Systematic Review and Meta-RegressionSystematic review · 2026 · Not peer reviewed · Not yet reviewed
• Sex and Socioeconomic Differences in the Initiation of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Patients With Type 2 Diabetes and Cardiovascular Disease: A Nationwide Cohort StudyRetrospective cohort · 2026 · Not yet reviewed
• Duration of GLP-1 Receptor Agonist Therapy and Nephrolithiasis Risk in Type 2 Diabetes: A Multicenter Retrospective Cohort StudyRetrospective cohort · 2026 · Not peer reviewed · Not yet reviewed
• Reprogramming NAD+ homeostasis and FOXO3a-Nrf2 signaling mitigates bleomycin-driven pulmonary fibrosisAnimal study · 2026 · Not yet reviewed
• Central Nervous System Effects of GLP-1 Receptor Agonists: A Systematic Review of Human Neuroimaging StudiesSystematic review · 2026 · Not yet reviewed
• Effects of Liraglutide and Semaglutide on Cardiometabolic Dysregulation and Oxidative Stress in an Experimental Model of Metabolic SyndromeAnimal study · 2026 · Not yet reviewed
• Comparing Cardiovascular Outcomes in New Users of Oral Semaglutide Versus Other Noninsulin Glucose-Lowering Therapies Among Adults with Type 2 Diabetes and Atherosclerotic Cardiovascular DiseaseRetrospective cohort · 2026 · Not yet reviewed
• Effects of semaglutide on subclinical cardiovascular health in people with HIVRandomized trial · 2026 · Not yet reviewed
• Semaglutide as adjunct treatment for obesity in adolescents receiving antipsychotic medication (the GOAL trial): protocol for a single-arm, open-label feasibility studyClinical trial · 2026 · Not yet reviewed
• Do Preoperative Glucagon-Like Peptide-1 Receptor Agonists Influence Lumbar Fusion Outcomes? A Systematic Review and Meta-AnalysisMeta-analysis · 2026 · Not yet reviewed
• Efficacy and Safety of Semaglutide According to Frailty Status: A Post Hoc Analysis of the SELECT Randomized Clinical TrialRandomized trial · 2026 · Not yet reviewed
• Long-Term Association Between GLP-1 Receptor Agonist Use and Incident Pancreatic Cancer: A Propensity Score-Matched Retrospective Cohort Study Using the TriNetX NetworkRetrospective cohort · 2026 · Not yet reviewed
• Peri-operative glucagon-like peptide-1 receptor agonist use and outcomes: a national prospective multicentre cohort studyRetrospective cohort · 2026 · Not yet reviewed
• Adjunctive GLP-1 receptor agonists for cardiometabolic risk in antipsychotic-treated patients: A GRADE-assessed meta-analysis of randomized trialsMeta-analysis · 2026 · Not yet reviewed
• Renal outcomes in people with type 2 diabetes with and without albuminuria treated with SGLT-2 inhibitors and GLP-1 receptor agonists: target trial emulationRetrospective cohort · 2026 · Not yet reviewed
• Glucagon-like Peptide-1 Receptor Agonists Are Not Associated with Increased Risk of Acute Pancreatitis or Pancreatic Complications, Including Pancreatic Cancer, in Type 2 Diabetes: A Global Propensity-Matched Cohort StudyRetrospective cohort · 2026 · Not yet reviewed
• Efficacy and safety of orforglipron 12 mg versus orforglipron 36 mg maintenance dose among patients with obesity with or without diabetes: a systematic review and comprehensive meta-analysisMeta-analysis · 2026 · Not yet reviewed
• Effectiveness of GLP-1 receptor agonists to prevent obstructive sleep apnea in patients with type 2 diabetes: active comparator, new user cohort studyRetrospective cohort · 2026 · Not yet reviewed
• GLP-1 receptor agonist use and mental health outcomes in adolescents with obesity: a retrospective reviewCase-control · 2026 · Not yet reviewed
• Prior GLP-1RA or Tirzepatide Use and Early Cardiorenal Outcomes After Metabolic and Bariatric SurgeryRetrospective cohort · 2026 · Not yet reviewed
• DUTCH weight control in atrial fibrillation study (DUTCH-WAIST) : Design and rationale of a randomised controlled trialRandomized trial · 2026 · Not yet reviewed
• Fracture-Centred Skeletal Reporting Profiles of Glucose-Lowering Drug Classes in FAERS and JADER: Cross-Database and Regional Reporting-Context AnalysesPharmacovigilance · 2026 · Not yet reviewed
• Obstructive sleep apnea, GLP-1 receptor agonist pharmacotherapy, and the oral microbiome: competing biological influences and implications for oral health monitoringPharmacovigilance · 2026 · Not yet reviewed
• Real-World Cost and Utilisation Burden of Diagnosed Metabolic Dysfunction-Associated Steatotic Liver Disease in Patients With Type 2 Diabetes in the United States: A Retrospective Cohort StudyRetrospective cohort · 2026 · Not yet reviewed
• Psychiatric Safety of GLP-1 and Dual GIP/GLP-1 Receptor Agonists in Adolescents With ObesityRetrospective cohort · 2026 · Not yet reviewed
• Effects of Renin-Angiotensin Inhibitors, Sodium-Glucose Cotransporter 2 Inhibitors, Mineralocorticoid Receptor Antagonists and Glucagon-Like Peptide 1 Receptor Agonists on Kidney Outcomes in Patients With Type 1 Diabetes: A Systematic Review and Meta-AnalysisMeta-analysis · 2026 · Not yet reviewed
• GLP-1 Receptor Agonists and Musculoskeletal Outcomes: A Systematic Literature Review and Meta-AnalysisMeta-analysis · 2026 · Not yet reviewed
• Metabolic Effects of a GLP-1 Analog Combined with Aerobic Training in Ovariectomized RatsAnimal study · 2026 · Not yet reviewed
• Glucagon-like peptide-1 receptor activation, inflammation and heart failure: Insights from genetic analysisMendelian randomization · 2026 · Not yet reviewed
• Postoperative outcomes after total knee arthroplasty in type 2 diabetes mellitus patients receiving semaglutide versus tirzepatide: a propensity score-matched national research network analysisRetrospective cohort · 2026 · Not yet reviewed
• Preoperative GLP-1 receptor agonist use and outcomes after total hip arthroplasty: a matched cohort studyRetrospective cohort · 2026 · Not yet reviewed
• Assessing the Association Between GLP-1 Receptor Agonists and Diabetic Foot Complications Using Real-World Pharmacovigilance Database and Mendelian RandomizationMendelian randomization · 2026 · Not yet reviewed
• Combination of genetic eNOS deficiency and high-fat diet induces reproducible cardiometabolic HFpEFAnimal study · 2026 · Not yet reviewed
• Clinical outcomes associated with GLP-1 receptor agonist use in metabolic dysfunction-associated steatohepatitis: A multinational cohort studyRetrospective cohort · 2026 · Not yet reviewed
• Side effects of lower dose compounded semaglutide paired with a behavioral management program: A real-world retrospective studyRetrospective cohort · 2026 · Not peer reviewed · Not yet reviewed
• Comparative outcomes for tirzepatide versus glucagon-like peptide-1 receptor agonists in patients with inflammatory bowel disease: a national propensity matched studyRetrospective cohort · 2026 · Not yet reviewed
• Carbon Emission Impact of Semaglutide in People with Obesity in the UK Using a Disease Modelling ApproachRetrospective cohort · 2026 · Not yet reviewed
• Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists as Adjuncts to Insulin Therapy in Type 1 Diabetes Mellitus: An Overlap-Informed Umbrella ReviewUmbrella review · 2026 · Not yet reviewed
• A Comparison of Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors in Reducing the Incidence of Tuberculosis and Mortality in Patients with DiabetesRetrospective cohort · 2026 · Not peer reviewed · Not yet reviewed
• Tirzepatide and the Incidence of Atrial Fibrillation in Adults With Overweight or Obesity: An Updated Meta-Analysis of Randomized Controlled TrialsMeta-analysis · 2026 · Not yet reviewed
• A retrospective cohort study on the comparative safety of glucagon-like peptide-1 receptor agonists versus dipeptidyl peptidase-4 inhibitors on the onset of gallbladder disease in type II diabetesRetrospective cohort · 2026 · Not yet reviewed
• Association of GLP-1 Receptor Agonists Versus Other Antidiabetic Medications With Cardiovascular, Renal, and Liver Outcomes in Patients With Type 2 DiabetesRetrospective cohort · 2026 · Not yet reviewed
• Finerenone-Based Dual Versus Triple Therapy with SGLT2 Inhibitors and GLP-1 Receptor Agonists in Type 2 Diabetes Mellitus Associated Chronic Kidney Disease: A Retrospective Cohort StudyRetrospective cohort · 2026 · Not yet reviewed
• Vagal activity related events and glucagon-like peptide-1 receptor agonistsRetrospective cohort · 2026 · Not yet reviewed
• Delayed gastric emptying in adolescent patients on GLP-1 receptor agonists with standard preoperative fasting guidelines: a prospective cohort studyProspective cohort · 2026 · Not yet reviewed
• Education and Alzheimer Disease Genetic Risk in Associations of GLP-1 Receptor Agonists With Dementia Among Adults With Type 2 DiabetesRetrospective cohort · 2026 · Not peer reviewed · Not yet reviewed
• Semaglutide and Papillary Thyroid Carcinoma: Current Evidence on Risk, Progression, and MechanismsPharmacovigilance · 2026 · Not peer reviewed · Not yet reviewed
• Liraglutide Ameliorates Atrial Fibrillation in Association with Enhanced Adiponectin Signaling in Epicardial Adipose TissueAnimal study · 2026 · Not yet reviewed
• Obesity in the GLP-1 Era: Clinical Characteristics and Prescribing Patterns in a Large Integrated Health SystemRetrospective cohort · 2026 · Not peer reviewed · Not yet reviewed
• Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy: Notoriety Bias or True Ocular Toxicity?Mendelian randomization · 2026 · Not peer reviewed · Not yet reviewed
• Dorsomedial striatal GABA dynamics organize palatable reward consumption and are reshaped by GLP-1 receptor agonismAnimal study · 2026 · Not peer reviewed · Not yet reviewed
• The effects of tirzepatide and semaglutide on clinical and metabolic outcomes in patients with heart failure with preserved ejection fraction and obesity: a systematic review and meta-analysisMeta-analysis · 2026 · Not yet reviewed
• Impact of GLP-1 Dose Intensity on Perioperative and Long-Term Fusion Outcomes Following ACDFRetrospective cohort · 2026 · Not yet reviewed
• GLP-1 receptor agonists vs DPP-4 inhibitors and neuropathic complications in type 2 diabetesRetrospective cohort · 2026 · Not yet reviewed
• The impact of glucagon-like peptide-1 (GLP-1) receptor agonists on postoperative outcomes following rotator cuff repairRetrospective cohort · 2026 · Not yet reviewed
• Sodium-Glucose Cotransporter-2 Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists, and Incident Atrial Fibrillation in Type 2 Diabetes: A Population-Based Target Trial EmulationRetrospective cohort · 2026 · Not yet reviewed
• HIF-1 plays a dual regulatory role in hippocampal neuronal PANoptosis in Alzheimer's disease via the HK2/VDAC1/NLRP3 axis and RIPK3 signalingAnimal study · 2026 · Not yet reviewed
• GLP-1 receptor agonist use is associated with shorter survival in patients with amyotrophic lateral sclerosis and diabetes mellitusRetrospective cohort · 2026 · Not peer reviewed · Not yet reviewed
• Safety and Glycemic Efficacy of Perioperative Liraglutide in Cardiac Surgery: A Systematic Review and Meta-Analysis of Randomized Controlled TrialsMeta-analysis · 2026 · Not yet reviewed
• Liraglutide Attenuates Hepatocyte Ferroptosis in an In Vitro Model of Metabolic Dysfunction-Associated Steatotic Liver DiseaseCell / in-vitro · 2026 · Not yet reviewed
• Tirzepatide preserves hematopoietic stem and progenitor cycling while remodeling inflammatory monocytes in obese miceAnimal study · 2026 · Not peer reviewed · Not yet reviewed
• GLP-1-based treatments and long-term clinical outcomes in MASLD amongst older adults: a retrospective cohort studyRetrospective cohort · 2026 · Not yet reviewed
• Postmarketing Safety Signals and Medication-Use Risks of GLP-1-Based Therapies in Diabetes and Obesity: A Multi-Source Pharmacovigilance and Regulatory Evidence-Mapping StudyPharmacovigilance · 2026 · Not yet reviewed
• GLP1-RA Use and Risk of Non-arteritic Anterior Ischemic Optic Neuropathy in Patients with Type 2 DiabetesRetrospective cohort · 2026 · Not yet reviewed
• Use of Glucose-Lowering Drugs for Type 2 Diabetes Among Danish Care Home ResidentsRetrospective cohort · 2026 · Not yet reviewed
• Glucagon-like Peptide-1 Receptor Agonist-Associated Injection Site and Dermatologic ReactionsPharmacovigilance · 2026 · Not yet reviewed
• What is the association between insulin dependence and the incidence of postoperative complications, perioperative glucose control, and five-year reoperation rates after total joint replacement?Retrospective cohort · 2026 · Not yet reviewed
• The GLP-1 Nutritional Paradox: A Global Meta-Analysis of Sarcopenic Risks and Micronutrient Gaps in the Post-Obesity EraMeta-analysis · 2026 · Not peer reviewed · Not yet reviewed
• Real-World EHR Signals from a Cohort of Blinded Incretin Trial Participants Motivate Novel Indication OpportunitiesRetrospective cohort · 2026 · Not peer reviewed · Not yet reviewed
• The Impact of Glucagon-like Peptide-1 (GLP-1) Receptor Agonists on Body Composition in Individuals with Overweight and Obesity: A Systematic Review and Meta-AnalysisMeta-analysis · 2026 · Not yet reviewed
• Semaglutide Attenuates Inflammatory Macrophage Polarization and Promotes Changes Associated with Mitochondrial Biogenesis Through cAMP-Dependent SignalingCell / in-vitro · 2026 · Not yet reviewed
• Microbiome and Metabolomics in Obesity: Advances in Understanding and Interventions Across the LifespanProspective cohort · 2026 · Not yet reviewed
• Integrating the liver into the cardiovascular-kidney-metabolic syndrome: pathophysiology and therapeutic implicationsRetrospective cohort · 2026 · Not yet reviewed
• Cardiometabolic outcomes of once-weekly IcoSema in adults with type 2 diabetes: systematic review and meta-analysis of the COMBINE trialsMeta-analysis · 2026 · Not yet reviewed
• Comparative Short-term Risk of Severe Gastrointestinal Events Associated With Opioid Type Among Patients Receiving Glucagon-Like Peptide-1 Receptor AgonistsRetrospective cohort · 2026 · Not yet reviewed
• Multi-Database Pharmacovigilance Analysis of Gastroesophageal Reflux Disease Associated with GLP-1 Receptor Agonists: A Cross-National Signal Validation StudyPharmacovigilance · 2026 · Not yet reviewed
• Glucagon-like Peptide-1 Receptor Agonist Use and Risk of Postmastectomy Lymphedema in Breast Cancer Survivors: A Multicenter Real-World Cohort StudyRetrospective cohort · 2026 · Not peer reviewed · Not yet reviewed
• GLP-1/GIP Uptake, Indication, and Access Pathways Among US Adults in the Understanding America StudyProspective cohort · 2026 · Not peer reviewed · Not yet reviewed
• Combination GLP-1RA and Low-Dose IL-2 Modulates Peripheral Immune Activation and Attenuates CNS Inflammatory Transcript Signatures In VivoAnimal study · 2026 · Not yet reviewed
• Effect of Combination Therapy with SGLT2 Inhibitors and GLP-1 Receptor Agonists on Myocardial Infarction and Stroke in Type 2 Diabetes: A Systematic Review and Meta-AnalysisMeta-analysis · 2026 · Not yet reviewed
• Investigating the Relationship Between Glucagon-Like Peptide-1 Receptor Agonist Use and Incidence of Vertebral Fractures in Female Patients Aged Over 50 Years With Osteoporosis: A Propensity-Matched AnalysisRetrospective cohort · 2026 · Not yet reviewed
• Genetic and Clinical Determinants of Variation in Drug Response in Type 2 Diabetes: Insights From the Scottish and UK Biobank CohortsRetrospective cohort · 2026 · Not yet reviewed
• Higher semaglutide dose is associated with lower neuropsychiatric event incidence independent of weight lossRetrospective cohort · 2026 · Not yet reviewed
• Clinical Evidence of Skin Improvements With a Biologically Active Multimodal Topical Skin TreatmentClinical trial · 2026 · Not yet reviewed
• Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists and Co-agonists for Weight Loss Among Adults Without Diabetes : An Updated Systematic ReviewSystematic review · 2026 · Not yet reviewed
• Study on the Regulatory Mechanism of GLP-1 Receptor Agonist Liraglutide in Diabetic Corneal Epithelial Wound HealingAnimal study · 2026 · Not yet reviewed
• Early GLP-1 Receptor Agonist Therapy in Acute Ischemic Stroke and High-Risk Transient Ischemic Attack: A Systematic Review and Meta-analysis of Randomized TrialsMeta-analysis · 2026 · Not yet reviewed
• Cardiorenal Protection in Type 2 Diabetes: A Systematic Review Comparing Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 InhibitorsSystematic review · 2026 · Not yet reviewed
• Efficacy and Safety of Tirzepatide Versus Dulaglutide in Type 2 Diabetes With or Without Established Atherosclerotic Cardiovascular Disease: A Network Meta-Analysis of Randomized Clinical TrialsMeta-analysis · 2026 · Not yet reviewed
• Comparative effectiveness of GLP-1 receptor agonists versus mineralocorticoid receptor antagonists as fourth-line pharmacological therapy in patients with resistant hypertension and overweight or obesity: a retrospective multicenter cohort study in the USARetrospective cohort · 2026 · Not yet reviewed
• Comparative Cardiovascular Outcomes of GLP-1 Receptor Agonists Versus Bariatric Surgery: A Systematic Review and Network Meta-AnalysisMeta-analysis · 2026 · Not yet reviewed
• Effects of Glucagon-Like Peptide-1 Receptor Agonist Use After Transient Ischemic Attack on Risks of Subsequent Ischemic Stroke and MortalityRetrospective cohort · 2026 · Not yet reviewed
• Late-life semaglutide treatment slows ageing and extends lifespan in female miceAnimal study · 2026 · Not yet reviewed
• Weight Regain Trajectories After Discontinuation of Semaglutide or Tirzepatide: A Reconstructed Aggregate-Data Bayesian Longitudinal Meta-AnalysisMeta-analysis · 2026 · Not yet reviewed
• Real-World Body Composition and Blood Pressure Changes Following Glucagon-Like Peptide 1 Receptor Agonist Initiation: A Causal Inference Study of Connected Device DataRetrospective cohort · 2026 · Not yet reviewed
• Low Preoperative Free Triiodothyronine, Particularly in Females, Is Associated With Reduced Weight Loss and Diabetes Remission After Bariatric Surgery in Euthyroid AdultsRetrospective cohort · 2026 · Not yet reviewed
• Effect of Retatrutide, a Novel Triple Receptor Agonist, on Blood Pressure and Lipid Levels: A Systematic Review and Meta-analysis of Randomized Controlled TrialsMeta-analysis · 2026 · Study tier 2 · Population unclear · Unclear
• Impact of Glucagon-Like Peptide-1 Receptor Agonists on Mental Health: A Systematic Review of Psychiatric Safety and Antidepressant PotentialSystematic review · 2026 · Not yet reviewed
• Comparative Efficacy and Safety of Liraglutide Versus Metformin in Women With Polyendocrine Metabolic Ovarian Syndrome (PMOS): A Systematic Review and Meta-Analysis of Randomized Controlled TrialsMeta-analysis · 2026 · Not yet reviewed
• Sex in CKD trials: representation and treatment effects of cardiorenoprotective therapiesRetrospective cohort · 2026 · Not yet reviewed
• Association of tirzepatide with changes in OSA-related measures based on baseline characteristics - post hoc analyses of SURMOUNT-OSARandomized trial · 2026 · Not yet reviewed
• Combined GLP-1 Receptor Agonist and SGLT2 Inhibitor Therapy for Adults with Type 2 Diabetes and Chronic Obstructive Pulmonary Disease: A Large-Scale Target Trial EmulationRetrospective cohort · 2026 · Not peer reviewed · Not yet reviewed
• GLP-1 Receptor Agonist Initiation and Anti-VEGF Treatment Frequency in Diabetic Macular Edema: an IRIS ^® Registry Cohort StudyRetrospective cohort · 2026 · Not peer reviewed · Not yet reviewed
• Assessing Type 2 Diabetes and GLP-1 agonist response trajectories with a proteogenomic atlas of disease progressionMendelian randomization · 2026 · Not peer reviewed · Not yet reviewed
• Neuropsychiatric Outcomes Associated with GLP-1 Receptor Agonists in Adults with Overweight or Obesity: A Systematic ReviewSystematic review · 2026 · Not yet reviewed
• Intrathecal semaglutide attenuates burn injury-induced pain in mice through a spinal GLP-1R-linked enkephalin/δ-opioid receptor pathwayAnimal study · 2026 · Not yet reviewed
• Effects of subcutaneous semaglutide on weight loss and inflammatory markers in adults with overweight or obesity without diabetes: a systematic review and meta-analysisMeta-analysis · 2026 · Study tier 2 · Different population · Unclear
• Comparative Efficacy of Promising Targets in the Treatment of Metabolic Dysfunction-associated Steatotic Liver Disease and Steatohepatitis: A Systematic Review and Network Meta-analysisMeta-analysis · 2026 · Not yet reviewed
• FDA prescribing information: Zepbound, ZEPBOUND (TIRZEPATIDE) - label effective 2026-08-28Regulatory document · 2026 · Not peer reviewed · Not yet reviewed
• Data-Driven Multidimensional Clinical Phenotypes and Longitudinal Changes in Type 2 Diabetes Mellitus: A Retrospective Cohort StudyRetrospective cohort · 2026 · Not yet reviewed
• Genetic Assessment of Oesophageal Safety of GLP-1 and GIP Receptor Perturbation: A Drug-Target Mendelian Randomisation StudyMendelian randomization · 2026 · Not yet reviewed
• Liraglutide Attenuates Multiorgan Oxidative, Astroglial, and Mitochondrial Stress Responses in Thioacetamide-Induced Hepatic EncephalopathyAnimal study · 2026 · Not yet reviewed
• Tirzepatide versus GLP-1 receptor agonists and stroke in patients with atrial fibrillation and type 2 diabetesRetrospective cohort · 2026 · Not yet reviewed
• Effect of Semaglutide on the Inflammatory Biomarker High-Sensitivity CRP in Patients With Established Cardiovascular Disease and Overweight or Obesity in SELECT: A Prespecified Secondary AnalysisPrespecified secondary (sub-study) analysis of a randomized, double-blind, placebo-controlled, parallel-group phase 3 trial (select) · 2026 · Study tier 2 · Different population · Benefit · Industry funded
• Retatrutide-Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 DiabetesRandomized trial · 2026 · Study tier 3 · Different population · Mixed
• Comprehensive Long-Term Changes in Cardiovascular Risk Biomarkers With Tirzepatide: A SURMOUNT-1 Post Hoc AnalysisRandomized trial · 2026 · Not yet reviewed
• Direct Coronary Vascular and Lipidomic Remodeling by Low-Dose GLP-1 Agonist Therapy in Cardiometabolic HFpEFAnimal study · 2026 · Not peer reviewed · Not yet reviewed
• Treatment strategies for functional hypogonadism in obese men: a systematic review and network meta-analysisMeta-analysis · 2026 · Not yet reviewed
• The GLP-1-Mitochondria Axis in Metabolic AgingMechanistic review · 2026 · Not rated · Not human evidence · Unclear
• Comparative Efficacy and Safety of Tirzepatide Versus Semaglutide for Obesity: A Systematic ReviewSystematic review · 2026 · Not yet reviewed
• Diabetes, Adiposity, and Functional Phenotypes in HFpEF: A Systematic Review of Recent Treatment-Response EvidenceSystematic review · 2026 · Not yet reviewed
• Neuropsychiatric Effects of Glucagon-Like Peptide-1 Receptor Agonists in Schizophrenia-Spectrum Disorders: A Systematic ReviewSystematic review · 2026 · Not yet reviewed
• Incretin-Based Therapies Versus Bariatric and Metabolic Surgery for Obesity and Type 2 Diabetes Mellitus: A Head-to-Head Systematic Review of Glycaemic, Cardiovascular, Hepatic, Weight, and Quality-of-Life OutcomesSystematic review · 2026 · Not yet reviewed
• Suspected Biphasic Anaphylaxis Following the First Known Dose of Tirzepatide: A Case Report and Brief Review of Reported Hypersensitivity ReactionsPharmacovigilance · 2026 · Not yet reviewed
• Short-Term Combined Treatment With Tirzepatide and Metformin for Overweight/Obese Chinese Women With Polycystic Ovary Syndrome: A Prospective, Open-Label, Randomised Controlled TrialRandomized trial · 2026 · Not yet reviewed
• Tirzepatide therapy reduces subclinical leaflet thrombosis and paravalvular leak after transcatheter aortic valve replacement in obese patients: The TAVR-MET trialRandomized trial · 2026 · Not yet reviewed
• Investigating the Association Between Semaglutide Use and Mood Disorders in Polyendocrine Metabolic Ovarian Syndrome: A Retrospective Cohort Study​Retrospective cohort · 2026 · Not yet reviewed
• Long-Term Clinical Outcomes and Real-World Effectiveness of Tirzepatide in Adults With Overweight or Obesity: A Systematic ReviewSystematic review · 2026 · Not yet reviewed
• Dapagliflozin Alone or Combined With Semaglutide: Cardiovascular and Renal Outcomes Among Patients With Type 2 Diabetes Mellitus in a 6-Month Real-World Retrospective Cohort Study in Saudi ArabiaRetrospective cohort · 2026 · Not yet reviewed
• Cardiovascular outcome of glucagon-like peptide-1 receptor agonists vs dipeptidyl peptidase-4 inhibitor on end-stage kidney disease patients with heart failure: an emulated target trial in patients with diabetesRetrospective cohort · 2026 · Not yet reviewed
• FDA prescribing information: Ozempic (SEMAGLUTIDE) - label effective 2026-07-30Regulatory document · 2026 · Not peer reviewed · Not yet reviewed
• FDA prescribing information: MOUNJARO (TIRZEPATIDE) - label effective 2026-07-29Regulatory document · 2026 · Not peer reviewed · Not yet reviewed
• FDA prescribing information: Liraglutide (LIRAGLUTIDE) - label effective 2026-07-27Regulatory document · 2026 · Not peer reviewed · Not yet reviewed
• Cardiovascular Outcomes of GLP-1-Based Medicines Among People With Overweight and Obesity: An Umbrella Review of Meta-Analyses of Randomized Controlled TrialsUmbrella review · 2026 · Study tier 2 · Different population · Mixed
• Prevention of Vascular Aging as a Novel Paradigm for GLP-1 Receptor Agonist-Mediated CardioprotectionMechanistic review · 2026 · Not rated · Not human evidence · Unclear
• Effects of Tirzepatide in Obesity-Related HFpEF by Sex: A Prespecified Secondary Analysis From the SUMMIT TrialRandomized trial · 2026 · Not yet reviewed
• Effects of Semaglutide on Body Composition and GFR: A Prespecified Analysis of the SMART TrialRandomized trial · 2026 · Study tier 3 · Different population · Mixed · Industry funded
• Apitegromab for lean mass preservation during tirzepatide-induced weight loss: a randomized, double-blind, placebo-controlled phase 2 trialRandomized trial · 2026 · Study tier 3 · Different population · Mixed · Industry funded
• Autoimmune Disease Risk With GLP-1RA, DPP-4i, and SGLT2i Treatment in Patients With DiabetesRetrospective cohort · 2026 · Study tier 4 · Different population · Mixed
• Effects of exercise and liraglutide on vascular health and inflammation during weight loss maintenance: a prespecified secondary analysis of the S-LiTE trialRandomized trial · 2026 · Not yet reviewed
• Short-term comparative effects of semaglutide, either alone or in conjunction with canagliflozin, on early diabetic kidney diseaseRandomized trial · 2026 · Not yet reviewed
• FDA prescribing information: Trulicity (DULAGLUTIDE) - label effective 2026-06-16Regulatory document · 2026 · Not peer reviewed · Not yet reviewed
• Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trialRandomized trial · 2026 · Study tier 2 · Different population · Benefit · Industry funded
• Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trialsRandomized trial · 2026 · Study tier 1 · Partial match · Null · Industry funded
• Rationale, design and baseline characteristics of the TRANSCEND-CKD trial of retatrutide in patients with chronic kidney diseaseClinical trial · 2026 · Study tier 4 · Different population · Unclear · Industry funded
• FDA prescribing information: Exenatide (EXENATIDE) - label effective 2026-05-27Regulatory document · 2026 · Not peer reviewed · Not yet reviewed
• Effects of Semaglutide on Cognitive Function in People With HIV: A Randomized, Controlled TrialRandomized trial · 2026 · Not yet reviewed
• Retatrutide And Lipid And Metabolite Profiles In Participants With Obesity With Or Without Type 2 DiabetesRandomized trial · 2026 · Study tier 2 · Different population · Benefit
• Efficacy and safety of GLP-1 receptor agonists in Parkinson's disease: a systematic review and meta-analysis of randomized clinical trialsMeta-analysis · 2026 · Study tier 2 · Partial match · Null
• Oral Semaglutide and Change in Cardiovascular Risk Factors in High-Risk Type 2 Diabetes: A Post Hoc Secondary Analysis of the SOUL Randomized Clinical TrialRandomized trial · 2026 · Not yet reviewed
• Semaglutide-associated risk of nonarteritic anterior ischemic optic neuropathy in patients with type 2 diabetes: A systematic review and meta-analysis of observational studiesMeta-analysis · 2026 · Study tier 3 · Different population · Harm direction
• Incretin-Based Therapies in Obesity-Related Heart Failure With Preserved Ejection Fraction (HFpEF): A Systematic Review of Emerging Cardiometabolic Disease Modification Beyond Glycemic ControlSystematic review · 2026 · Not yet reviewed
• Tirzepatide Beyond Diabetes and Obesity: Systematic Review and Meta-Analysis of Multisystem Therapeutic BenefitsMeta-analysis · 2026 · Not yet reviewed
• FDA prescribing information: Soliqua 100/33 (INSULIN GLARGINE AND LIXISENATIDE) - label effective 2026-03-18Regulatory document · 2026 · Not peer reviewed · Not yet reviewed
• Comparative Efficacy and Safety of Glucagon Receptor Agonists on Metabolic Outcomes: A Network Meta-Analysis of Randomised Controlled TrialsMeta-analysis · 2026 · Study tier 2 · Different population · Unclear
• Incretin-Based Dual and Triple Agonists in Overweight or Obese Individuals: A Systematic Review and Meta-AnalysisMeta-analysis · 2026 · Study tier 2 · Different population · Mixed
• Tirzepatide on obstructive sleep apnea-related cardiometabolic risk: secondary outcomes of the SURMOUNT-OSA randomized trialRandomized trial · 2026 · Not yet reviewed
• FDA prescribing information: OZEMPIC, RYBELSUS (ORAL SEMAGLUTIDE) - label effective 2026-01-30Regulatory document · 2026 · Not peer reviewed · Not yet reviewed
• FDA prescribing information: Liraglutide (LIRAGLUTIDE) - label effective 2026-01-30Regulatory document · 2026 · Not peer reviewed · Not yet reviewed
• Effect of glucagon-like peptide-1 receptor agonists on heart rate in non-diabetic individuals with overweight or obesity: a systematic review and pairwise and network meta-analysis of randomized controlled trialsMeta-analysis · 2026 · Study tier 2 · Different population · Harm direction
• Liraglutide in mild to moderate Alzheimer's disease: a phase 2b clinical trialRandomized trial · 2026 · Study tier 3 · Partial match · Mixed · Partly industry funded
• Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trialsTrial registration · 2026 · Preliminary · Different population · Unclear · Industry funded
• Long-Term Cardiovascular Outcomes of Glucagon-Like Peptide-1 Receptor Agonists in Non-diabetic Obesity: A Systematic Review and Meta-AnalysisMeta-analysis · 2026 · Study tier 2 · Different population · Mixed
• Effect of Glucagon-Like Peptide-1 Receptor Agonists on Cardiometabolic Risk Factors in Type 1 Diabetes Mellitus: A Systematic Review and Meta-AnalysisMeta-analysis · 2026 · Not yet reviewed
• Tirzepatide and the risk of asthma exacerbations in patients with type 2 diabetesRetrospective cohort · 2026 · Not yet reviewed
• Prehospital glucagon-like peptide-1 receptor agonists are not associated with reduced inpatient opioid exposure but with shorter hospital length of stay after total joint arthroplastyRetrospective cohort · 2026 · Not yet reviewed
• Weight regain following discontinuation of glucagon-like peptide-1 receptor agonists in adults who are overweight or obese: a systematic review and meta-analysisMeta-analysis · 2026 · Not yet reviewed
• Effects of GLP-1 receptor agonists on the incidence of contrast-induced acute kidney injury in patients with Type 2 diabetes mellitus undergoing coronary interventionsRetrospective cohort · 2026 · Not yet reviewed
• Associations Between Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) and Cancer Risk: A Systematic Review and Meta-AnalysisMeta-analysis · 2026 · Not yet reviewed
• Efficacy of SGLT2 inhibitors, GLP-1 receptor agonists, and aerobic exercise for moderate-to-severe obstructive sleep apnea in overweight or obese patients: a network meta-analysisMeta-analysis · 2026 · Not yet reviewed
• Low baseline HbA1c and reduced eGFR are associated with relatively unfavorable body recomposition after SGLT2 inhibitor therapy in type 2 diabetesRetrospective cohort · 2026 · Not yet reviewed
• Impact of GLP-1 receptor agonists on patients with intraductal papillary mucinous neoplasms: Study protocol for a multicentric cohort studyRetrospective cohort · 2026 · Not yet reviewed
• Reporting patterns of suicide- and self-injury-related events involving liraglutide, semaglutide, and tirzepatide: data from the European pharmacovigilance databasePharmacovigilance · 2026 · Not yet reviewed